Ardent Health, Inc. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 42/100
What the filing says
Ardent Health reported Q3 2026 revenue of $1.625B (+3.1% YoY) and net income of $45M ($0.31/share) versus Q3 2025 loss of $23M. Adjusted EBITDA of $138M included benefits from IMPACT cost-reduction initiatives (targeting $70M+ annual savings). The company raised full-year 2026 Adjusted EBITDA guidance midpoint to $517.5M from $510M (+1.5%), while reaffirming revenue guidance of $6.4B–$6.7B. Ardent entered a definitive agreement to transition full ownership of its Kansas hospital to a joint venture partner to enhance margins and redeploy capital. Cash position: $766M; leverage: 0.8x net, 2.5x lease-adjusted net.
Why this rating
Modest operational beat and cost discipline support continued stability; guidance raise is incremental (+1.5%), not transformational. Asset sale is portfolio optimization, not transformational M&A. At ~$324M market cap, $45M quarterly profit is meaningful but not exceptional. No major structural changes.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.